Oslo, Q8CIK 14753734 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
36 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Bristol-Myers Squibb Co | 746.0K | $40.24M | 9.2% | +164.7K | Added |
| 2 | Merck & Co Inc | 363.7K | $38.28M | 8.7% | +41.2K | Added |
| 3 | Medtronic PLC | 269.6K | $25.90M | 5.9% | −33.8K | Reduced |
| 4 | Becton Dickinson & Co |
| 132.4K |
| $25.69M |
| 5.9% |
| +23.5K |
| Added |
| 5 | Gilead Sciences Inc | 176.4K | $21.65M | 4.9% | +29.2K | Added |
| 6 | Incyte Corp | 218.8K | $21.61M | 4.9% | +13.7K | Added |
| 7 | Pfizer Inc | 859.5K | $21.40M | 4.9% | −392.5K | Reduced |
| 8 | Amgen Inc | 61.0K | $19.95M | 4.5% | −500 | Reduced |
| 9 | Biogen Inc | 85.5K | $15.04M | 3.4% | +10.0K | Added |
| 10 | Ionis Pharmaceuticals Inc | 185.0K | $14.63M | 3.3% | −86.0K | Reduced |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio